A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.
dc.contributor.author | Tsuda, Yoshimi | |
dc.contributor.author | Caposio, Patrizia | |
dc.contributor.author | Parkins, Christopher J | |
dc.contributor.author | Botto, Sara | |
dc.contributor.author | Messaoudi, Ilhem | |
dc.contributor.author | Cicin-Sain, Luka | |
dc.contributor.author | Feldmann, Heinz | |
dc.contributor.author | Jarvis, Michael A | |
dc.date.accessioned | 2012-03-01T15:40:56Z | |
dc.date.available | 2012-03-01T15:40:56Z | |
dc.date.issued | 2011-08 | |
dc.identifier.citation | A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. 2011, 5 (8):e1275 PLoS Negl Trop Dis | en |
dc.identifier.issn | 1935-2735 | |
dc.identifier.pmid | 21858240 | |
dc.identifier.doi | 10.1371/journal.pntd.0001275 | |
dc.identifier.uri | http://hdl.handle.net/10033/213809 | |
dc.description.abstract | Human outbreaks of Ebola virus (EBOV) are a serious human health concern in Central Africa. Great apes (gorillas/chimpanzees) are an important source of EBOV transmission to humans due to increased hunting of wildlife including the 'bush-meat' trade. Cytomegalovirus (CMV) is an highly immunogenic virus that has shown recent utility as a vaccine platform. CMV-based vaccines also have the unique potential to re-infect and disseminate through target populations regardless of prior CMV immunity, which may be ideal for achieving high vaccine coverage in inaccessible populations such as great apes. | |
dc.language.iso | en | en |
dc.subject.mesh | Animals | en |
dc.subject.mesh | CD8-Positive T-Lymphocytes | en |
dc.subject.mesh | Drug Carriers | en |
dc.subject.mesh | Ebola Vaccines | en |
dc.subject.mesh | Ebolavirus | en |
dc.subject.mesh | Epitopes, T-Lymphocyte | en |
dc.subject.mesh | Female | en |
dc.subject.mesh | Genetic Vectors | en |
dc.subject.mesh | Hemorrhagic Fever, Ebola | en |
dc.subject.mesh | Mice | en |
dc.subject.mesh | Mice, Inbred C57BL | en |
dc.subject.mesh | Muromegalovirus | en |
dc.subject.mesh | Nucleoproteins | en |
dc.subject.mesh | T-Lymphocytes, Cytotoxic | en |
dc.subject.mesh | Vaccines, Subunit | en |
dc.subject.mesh | Vaccines, Synthetic | en |
dc.title | A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. | en |
dc.type | Article | en |
dc.contributor.department | Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America. | en |
dc.identifier.journal | PLoS neglected tropical diseases | en |
refterms.dateFOA | 2018-06-13T07:45:15Z | |
html.description.abstract | Human outbreaks of Ebola virus (EBOV) are a serious human health concern in Central Africa. Great apes (gorillas/chimpanzees) are an important source of EBOV transmission to humans due to increased hunting of wildlife including the 'bush-meat' trade. Cytomegalovirus (CMV) is an highly immunogenic virus that has shown recent utility as a vaccine platform. CMV-based vaccines also have the unique potential to re-infect and disseminate through target populations regardless of prior CMV immunity, which may be ideal for achieving high vaccine coverage in inaccessible populations such as great apes. |